Clinical Trial Update: Oxytocin for Hypermobile Ehlers-Danlos Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating oxytocin for Hypermobile Ehlers-Danlos Syndrome has been terminated; results were posted on 2025-08-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypermobile Ehlers-danlos Syndrome

Drugs mentioned

• Oxytocin (Oxytocin)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hypermobile Ehlers-Danlos Syndrome, Pain Assessment | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-28